CRDL

Cardiol Therapeutics Inc.

Investor Moves

NameValueActionChangePriceLast Price
Ken GriffinCitadel Advisors
$1.2M896.5k shares
AddQ1 2026
$1.1M
$1.35
$1.28
Ken GriffinCitadel Advisors
$444.8K
AddQ3 2025
$445k
--
$1.28
Ken GriffinCitadel Advisors
$444.8K
AddQ3 2025
$445k
--
$1.28
Ken GriffinCitadel Advisors
$-85.8K
TrimQ3 2024
$86k
--
$1.28
Ken GriffinCitadel Advisors
$-85.8K
TrimQ3 2024
$86k
--
$1.28

News

prnewswire.comCardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQprnewswire.comMay 14prnewswire.comCardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Associationprnewswire.comMay 7prnewswire.comCardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Programprnewswire.comApr 28defenseworld.netContrasting Corcept Therapeutics (NASDAQ:CORT) & Cardiol Therapeutics (NASDAQ:CRDL)defenseworld.netApr 24newsfilecorp.comCardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchartnewsfilecorp.comApr 14